ReNeuron has released further data on the first three retinitis pigmentosa (RP) patients dosed with its human retinal progenitor cell (hRPC) product. Improvements in visual acuity have continued to the 60- and 120-day follow-up points. Although further and longer-duration data would be required for a regulator to consider an accelerated regulatory strategy, potential partners for the ex-China rights to ReNeuron’s hRPC product could act much sooner.
26 Apr 2019
ReNeuron Group - Early clinical data in RP continue to improve
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Early clinical data in RP continue to improve
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
26 Apr 2019 -
Author:
Dr Andy Smith -
Pages:
2
ReNeuron has released further data on the first three retinitis pigmentosa (RP) patients dosed with its human retinal progenitor cell (hRPC) product. Improvements in visual acuity have continued to the 60- and 120-day follow-up points. Although further and longer-duration data would be required for a regulator to consider an accelerated regulatory strategy, potential partners for the ex-China rights to ReNeuron’s hRPC product could act much sooner.